Second edition 2018-04

# Assessment of the safety of magnetic resonance imaging for patients with an active implantable medical device

Évaluation de la sécurité de l'imagerie par résonance magnétique pour les patients avec un dispositif médical implantable actif



# ISO/TS 10974:2018(E)

This is a preview of "ISO/TS 10974:2018". Click here to purchase the full version from the ANSI store.



### COPYRIGHT PROTECTED DOCUMENT

© ISO 2018

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office CP 401 • Ch. de Blandonnet 8 CH-1214 Vernier, Geneva Phone: +41 22 749 01 11 Fax: +41 22 749 09 47 Email: copyright@iso.org Website: www.iso.org

Published in Switzerland

Con	Contents		Page		
Forew	ord			vii	
Introd	luction			viii	
1					
2	_		erences		
3			initions		
4			bbreviated terms		
5	Gener	al requii	rements for non-implantable parts	6	
6	Requi	rements	for particular AIMDs	6	
7	General considerations for application of the tests of this document			6	
	7.1 Compliance criteria				
	7.2		ers		
	7.3		orts		
			General Description of the AIMD under test		
		7.3.2 7.3.3	Description of the AIMD under test		
8			m harm to the patient caused by RF-induced heating		
	8.1		ction		
	8.2 8.3		of the Stage 1 four-tier approachement system prerequisites for all tiers		
	0.5		RF field source		
			Tissue simulating phantom		
			Definition of power deposition		
			Measurement system validation		
	8.4		nation of RF-induced power deposition in a tissue simulating medium		
		8.4.1	General	12	
			Determine location of hot spots around the AIMD	13	
		8.4.3	Determination of spatial (3D) distribution of power deposition for each		
		0.4.4	hot spot		
	0.5		Determine the final power deposition		
	8.5		ty effect of electrodes from multiple leads		
	8.6 8.7		ng prerequisites for Tier 2, Tier 3, and Tier 4ection for RF-induced power deposition		
	0.7		General		
			Tier 1		
			Tier 2		
		8.7.4	Tier 3	19	
		8.7.5	Tier 4		
	8.8		model validation		
	8.9		uncertainty analysis		
	8.10		analysis of power deposition		
	8.11		ced heating assessment flow chart		
9	Prote	ction fro	m harm to the patient caused by gradient-induced device heating	27	
	9.1 9.2		ction		
	9.2		considerations		
			Determination of $ dB/dt $ rms exposure limits		
			Determination of lab/at   This exposure mints		
	9.3		uirements		
		-	General		
			In vitro test phantom or other suitable container		
		9.3.3	Gelled solution	30	

		9.3.4 Temperature survey to determine orientation and hot spots	30
		9.3.5 Minimum temperature instrumentation	31
		9.3.6 Definition of <i>dB/dt</i> test waveform	31
		9.3.7 Characterization of applied <i>dB/dt</i>	32
	9.4	Lab testing using simulated MR gradient field	
	9.5	MR scanner testing	
	9.6	Analysis of gradient heating test	33
10	Prote	ection from harm to the patient caused by gradient-induced vibration	33
	10.1	Introduction	
	10.2	Overview of tiers	34
	10.3	MR environmental conditions	35
		10.3.1 General	
		10.3.2 Determination of maximum clinical <i>dB/dt</i>	
		10.3.3 Determination of clinical $B_0$	
		10.3.4 Determination of clinical $dB/dt \times B_0$	
		10.3.5 Test frequencies	
		10.3.6 Test duration	
	10.4	10.3.7 Test temperature	
	10.4	General test procedure	
		10.4.1 Measurement of gradient field and determination of AIMD location	
	10.5	10.4.2 AIMD/test unit setup	
	10.5	Method 2 — Shaker table	
	10.0	10.6.1 General	
		10.6.2 Determine scanner input	
		10.6.3 AIMD vibration response	
		10.6.4 Determine shaker table amplitude ( <i>dB/dt</i> scaling)	
		10.6.5 Perform vibration exposure using a shaker table	
11	Droto	•	
11		ection from harm to the patient caused by B <sub>0</sub> -induced force	41
11 12		•	41
	Prote	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque	41
12	Prote Prote poten	ection from harm to the patient caused by $B_0$ -induced force section from harm to the patient caused by $B_0$ -induced torque section from harm to the patient caused by gradient-induced extrinsic electric ntial	41 41
12	Prote poten 13.1	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction	41414141
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ential entroduction General requirements	4141414142
12	Prote poten 13.1	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction  General requirements  Gradient pulse leakage test	4141414142
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction  General requirements  Gradient pulse leakage test  13.3.1 General	41 41 41 42 46
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment	414141424646
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by B <sub>0</sub> -induced force ection from harm to the patient caused by B <sub>0</sub> -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal	41414142464646
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by B <sub>0</sub> -induced torque	41414142464646
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by $B_0$ -induced force ection from harm to the patient caused by $B_0$ -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ential  Introduction  General requirements  Gradient pulse leakage test  13.3.1 General  13.3.2 Test equipment  13.3.3 Test signal  13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure  13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state	4141414246464648
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced torque	4141414246464648
12	Prote Prote poten 13.1 13.2	ection from harm to the patient caused by B <sub>0</sub> -induced force ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction  General requirements  Gradient pulse leakage test  13.3.1 General  13.3.2 Test equipment  13.3.3 Test signal  13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure  13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure  Gradient rectification test	4141 41 42 46 46 46 4848
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General	4141424646485153
12	Prote poten 13.1 13.2 13.3	ction from harm to the patient caused by B <sub>0</sub> -induced torque ction from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment	4141464646485353
12	Prote poten 13.1 13.2 13.3	ction from harm to the patient caused by B <sub>0</sub> -induced torque ction from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal	414142464646485353
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced torque.  Ection from harm to the patient caused by gradient-induced extrinsic electric intial.  Introduction General requirements Gradient pulse leakage test.  13.3.1 General.  13.3.2 Test equipment.  13.3.3 Test signal.  13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure.  13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure.  Gradient rectification test.  13.4.1 General.  13.4.2 Test equipment.  13.4.3 Test signal.  13.4.4 Gradient-induced rectification measurement test procedure.	414146464648535353
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced force ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test	41414246464853535353
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced force ection from harm to the patient caused by gradient-induced extrinsic electric ntial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test	4141424646464853535353
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced torque ection from harm to the patient caused by gradient-induced extrinsic electric ential  Introduction  General requirements  Gradient pulse leakage test  13.3.1 General  13.3.2 Test equipment  13.3.3 Test signal  13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure  13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure  Gradient rectification test  13.4.1 General  13.4.2 Test equipment  13.4.3 Test signal  13.4.4 Gradient-induced rectification measurement test procedure  Gradient pulse distortion of AIMD output test  13.5.1 General	4141464646485353535353
12	Prote poten 13.1 13.2 13.3	ection from harm to the patient caused by B <sub>0</sub> -induced torque	41414646464853535353535656
12 13	Prote potent 13.1 13.2 13.3 13.4 13.4	ction from harm to the patient caused by B <sub>0</sub> -induced torque.  ction from harm to the patient caused by gradient-induced extrinsic electric detail.  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test 13.5.1 General 13.5.2 Test equipment 13.5.3 Test signal 13.5.4 Gradient-induced AIMD output distortion test procedure	414142464648535353535656
12	Prote potent 13.1 13.2 13.3 13.4 13.4	ction from harm to the patient caused by B <sub>0</sub> -induced force ction from harm to the patient caused by gradient-induced extrinsic electric ctial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test 13.5.1 General 13.5.2 Test equipment 13.5.3 Test signal 13.5.4 Gradient-induced AIMD output distortion test procedure.	41414246464653535353565656
12 13	Prote poten 13.1 13.2 13.3 13.4 13.5	ction from harm to the patient caused by B <sub>0</sub> -induced torque ction from harm to the patient caused by gradient-induced extrinsic electric ctial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.5 Tier 2 — Separate transient gradient-induced charge measurement test procedure 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test 13.5.1 General 13.5.2 Test equipment 13.5.3 Test signal 13.5.4 Gradient-induced AIMD output distortion test procedure.  Cettion from harm to the patient caused by B <sub>0</sub> -induced malfunction Introduction	41414646464853535353565656
12 13	Prote poten 13.1 13.2 13.3 13.4 13.5 Prote 14.1	ction from harm to the patient caused by B <sub>0</sub> -induced force ction from harm to the patient caused by gradient-induced extrinsic electric ctial  Introduction General requirements Gradient pulse leakage test 13.3.1 General 13.3.2 Test equipment 13.3.3 Test signal 13.3.4 Tier 1 — Combined gradient-induced charge measurement test procedure 13.3.5 Tier 2 — Separate transient gradient-induced charge and steady-state current measurement test procedure Gradient rectification test 13.4.1 General 13.4.2 Test equipment 13.4.3 Test signal 13.4.4 Gradient-induced rectification measurement test procedure Gradient pulse distortion of AIMD output test 13.5.1 General 13.5.2 Test equipment 13.5.3 Test signal 13.5.4 Gradient-induced AIMD output distortion test procedure.	4141464646485353535356565656

		14.2.3 Test conditions	
	14.3	Test procedures	60
		14.3.1 General	60
		14.3.2 Class 0 test procedure	60
		14.3.3 Class 1 test procedure	
		14.3.4 Class 2 test procedure	61
15	Prote	ction from harm to the patient caused by RF-induced malfunction and RF	
		ication	61
	15.1	Introduction	
	15.2	General requirements	
	15.3	Mechanisms for RF interaction with an AIMD	
	15.4	Selecting radiated vs injected test methods	
		15.4.1 General	
		15.4.2 AIMD type designation for test method selection	
		15.4.3 RF antenna type designation for test method selection	
		15.4.4 RF EMC tier selection	
		15.4.5 RF test conditions	
		15.4.6 $B_0$ considerations	
	15.5	Injected immunity test	
		15.5.1 General	68
		15.5.2 Determination of peak and rms injected levels for Tier 1 and Tier	
		2 — AIMD with short electrical length	69
		15.5.3 Determination of peak and rms injected levels for Tier 3 and Tier 4	
		15.5.4 Injected immunity test procedure	
		15.5.5 RF phase test conditions	
	45.6	15.5.6 AIMD monitoring during the test	
	15.6	Radiated immunity test	
		15.6.1 General	
		15.6.2 Determining the RF radiated field level	
		15.6.3 Radiated test procedure	
	157	15.6.4 AIMD monitoring during the test	
	15.7	Test equipment	/ 3
		15.7.1 Generating the RF electric field for radiated testing (AIMD with short electrical length)	72
		15.7.2 Phantom and tissue simulating medium for radiated testing	
		15.7.2 Filantoni and dissue simulating medium for radiated testing	
		15.7.4 RF level measuring device 15.7.5 RF injection network	
	15.8	Determining the peak RF injected level using a radiated test	
4.0			
16	<b>Prote</b> 16.1	ction from harm to the patient caused by gradient-induced malfunction	76 76
	16.1	General requirements	
	16.3	Selecting radiated and injected test methods	
	16.4	Radiated immunity test	
	10.7	16.4.1 General	
		16.4.2 Test equipment	
		16.4.3 Radiated test signal	
		16.4.4 Test procedure	
	16.5	Injected immunity test	
	10.0	16.5.1 General	
		16.5.2 Test equipment	
		16.5.3 Injected test signal	
		16.5.4 Test procedure	
		16.5.5 AIMD test configuration	
17	Coml	oined fields test	
1/	17.1	Introduction	
	17.1	Test setup	
	1/.4	rest setup	ラサ

	17.3	AIMD fixation	
	17.4	Test procedure	
		17.4.1 General	
		17.4.2 Before MR exposure During MR exposure	
		17.4.4 After MR exposure	
	17.5	Test equipment	97
		17.5.1 Field generation	
		17.5.2 Phantom and tissue simulating medium	
40		5 11	
18	<b>Marki</b> 18.1	ngs and accompanying documentation  Definitions	
	18.2	Applicability of labelling requirements	
	18.3	Labelling requirements	
Annex	A (nor	mative) Pulsed gradient exposure for Clause 10, Clause 13, and Clause 16	100
Annex	B (info	ormative) Derivation of lead length factor for injected voltage test levels for	110
		e 13 and Clause 16	
	-	rmative) Tier 1 high tangential E-field trough line resonator	121
Annex		ormative) <b>Supporting information and rationale for gradient-induced device</b>	120
Annev		rmative) <b>Example RF injection network</b>	
		rmative) Supporting information and rationale for MR-induced vibration	
	-	ormative) Gradient vibration patent declaration form	
	•	· ·	
		ormative) Assessment of dielectric and thermal parameters	
	-	rmative) RF exposure system validation method	
		rmative) MR scanner RF transmit coil	156
Annex	K (info	ormative) Current distribution on the AIMD as a function of the phase	158
Annex		rmative) Tissue simulating medium formulations	
	•	ormative) <b>Generation of incident fields</b>	
	•	ormative) <b>Dielectric and thermal tissue properties</b>	
		ormative) Gradient field injected testing — AIMD electrode tissue impedance	
		nination method	184
Annex		rmative) Estimation of conservative B <sub>1</sub> and 10 g averaged E-field values for for RF-induced heating and RF malfunction	189
Annex		ormative) AIMD configuration	
Annex	R (info	ormative) Electrically excitable tissue stimulation, terms and definitions	198
Annex	S (info	rmative) Combined fields test	200
Annex	T (info	ormative) General methods for modelling dB/dt levels in MR gradient coils	206
Biblio	graphy		212

# Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see <a href="www.iso.org/directives">www.iso.org/directives</a>).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see <a href="www.iso.org/patents">www.iso.org/patents</a>).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: <a href="https://www.iso.org/iso/foreword.html">www.iso.org/iso/foreword.html</a>.

This document was prepared jointly by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 6, *Active implants*, and Technical Committee IEC TC 62, *Electrical equipment in medical practice*, Subcommittee SC 62B, *Diagnostic imaging equipment*. The draft was circulated for voting to the national bodies of both ISO and IEC.

This second edition cancels and replaces the first edition (ISO/TS 10974:2012) which has been technically revised.

# Introduction

The first edition (2012) of this document came about following a joint meeting between ISO/TC 150, *Implants for surgery*, and IEC/SC 62B/MT 40, *Magnetic resonance equipment for medical diagnosis*, in Vienna, Austria, in September 2006. An agreement was reached to coordinate efforts on the development of a new Technical Specification for the safety of patients with active implantable medical devices (AIMD) undergoing an MRI exam and related further development of IEC 60601-2-33.

This second edition represents experience gained from the first edition of its use in practice and the current understanding of relevant issues and concerns at 1,5 T, the most common MR field strength. The Joint Working Group (JWG) responsible for this document (ISO/TC 150/SC 6/JWG 2 and IEC/SC 62B/JWG 1) releases this edition to promote further developments in this area. The JWG anticipates the possibility that an International Standard might result from this work.

IEC 60601-2-33 provides supporting information. By mutual agreement between the JWG and MT 40, any and all MR scanner-related requirements will be considered by IEC/SC 62B/MT 40 and will be released through future amendments and editions of IEC 60601-2-33.

No requirements contained within this document, including the use of clinical scanners, construe or imply any obligation for compliance on the part of MR scanner manufacturers. Any statement to the contrary is strictly unintentional.

The relationship between product committees is shown in <u>Figure 1</u>. Straight lines represent the relationship and not necessarily a physical connection. Ellipses represent scope, i.e. the effects between patient and scanner, patient and AIMD, and AIMD and scanner.

The JWG is concerned with effects on the AIMD caused by the scanner. ISO/TC 150/SC 6 is concerned with resulting potential hazards to the patient caused by the AIMD. IEC 62B/MT40 is concerned with potential hazards to the patient caused by the MR scanner.




Figure 1 — Responsibilities of product committees illustrating the extent of the scope of this document in terms of the effects between AIMDs and MR scanners

The test methods contained in this document for evaluating device operation against several hazards are applicable to a broad class of AIMDs. Tests for particular device types are not included. Specific

compliance criteria and the determination of risk resulting from device behavioural responses during these tests are outside the scope of this document.

NOTE The device manufacturer, regulatory agencies and particular product committees, are responsible for setting specific compliance criteria and the determination of risk. For example, ISO/TC 150/SC 6 might turn the general provisions of this document into product-specific requirements.

The test methods in this document were derived from six known or foreseeable potential hazards to patients with an AIMD undergoing an MR scan. These general hazards give rise to specific test methods as shown in Table 1.

Table 1 — Potential patient hazards and corresponding test methods

General hazard	Test method	Clause
Heat	RF field-induced heating of the AIMD	8
	Gradient field-induced device heating	9
Vibration	Gradient field-induced vibration	<u>10</u>
Force	B <sub>0</sub> -induced force	<u>11</u>
Torque	$B_0$ -induced torque	12
Unintended stimulation	Gradient field-induced lead voltage (extrinsic electric potential)	13
	RF field-induced rectified lead voltage	<u>15</u>
Malfunction	$B_0$ field-induced device malfunction	14
	RF field-induced device malfunction	<u>15</u>
	Gradient field-induced device malfunction	<u>16</u>
	Combined fields test	<u>17</u>

Figure 2 depicts the relationship between the three output fields of an MR scanner (RF, gradient, and  $B_0$ ) and the hazards considered by this document. In the figure, extrinsic electric potential and RF rectification are represented as Unintended Stimulation and heat is shown as occurring from two sources, Electrode Heating and Device Heating. Numbers in parentheses indicate clause numbers. For example, RF field-induced heating of electrodes is evaluated according to the test method in Clause 8.




Figure 2 — Relationship between MR scanner output fields (RF, gradient,  $B_0$ ) and hazards (test method clause numbers in parentheses)

Evaluation of the AIMD for these hazards involves some combination of testing and modelling. Tests in <u>Clauses 8</u> through <u>16</u> may use bench-top testing, modelling, MR scanners, or a combination of these approaches. The test in <u>Clause 17</u> uses an MR scanner. Devices are subjected to radiated fields or injected voltages in order to witness behavioural responses. Modelling may be employed to determine appropriate test signal voltage levels or to estimate tissue heating, for example. Within this document device immunity to the  $B_0$ , RF, and gradient fields is evaluated separately, except for <u>Clause 17</u>.

In addition to the tests listed in <u>Table 1</u>, this document contains requirements for markings and accompanying documentation (<u>Clause 18</u>).

RF-induced heating of tissues surrounding an AIMD is caused by elevated local SAR and associated component heating that arises from induced currents.

Gradient-induced device heating is caused by eddy currents.

Device vibration is due to the combined effect of the  $B_0$  (static) and gradient fields.

Force and torque is caused by  $B_0$  (static) interaction with magnetic materials.

Extrinsic electric potential is meant to imply that the induced voltage comes from outside the device as in the case of gradient-induced stimulation or modification of output pulses due to superposition. The result involves voltages not caused by a device malfunction.

Rectification of induced voltages can occur if the induced voltage is high enough to cause nonlinear circuit elements to conduct, for example, an input protection diode. Rectification might result in voltage pulses occurring at a distal electrode. The resulting rectified voltage is an unintended consequence of the reaction of the AIMD and is not considered a device failure or malfunction, per se.

Malfunction is meant to capture a wide range of performance issues, such as degradation of performance, loss of function, unintentional responses, etc., due to device failure caused by, for example, the improper operation of a circuit element or motor. Since malfunctions are highly device-specific, and unknown in a general sense for all AIMD types, they remain undefined in this document.

This document applies to AIMDs that are intended to be introduced into certain MR environments. It applies only to AIMDs that do not use sensing functions or to AIMDs that are programmed not to use sensing functions to affect therapy delivery during an MR scan.

The Combined Fields Test establishes an *in vitro* evaluation of the AIMD functioning under simultaneous exposure to the static, gradient, and RF magnetic field conditions. Unlike the maximal exposures required in the tests for <u>Clauses 8</u> through <u>16</u>, the Combined Fields Test exposes the AIMD to levels and temporal patterns of all three MR scanner magnetic field outputs simultaneously. The Combined Field Test alone does not constitute a comprehensive assessment of device performance and should be considered as one part of the overall assessment process.

Test methods described in this document are primarily designed and intended as bench-top tests using equipment and techniques producing effects ( $B_0$  static, gradient, and RF) representative of those generated by MR 1,5 T scanners. The exception being <u>Clause 17</u>. Although, in a few cases, clinical scanner tests are implied, in all others, the AIMD manufacturer assumes the burden for development and validation of clinical scanner-based test methods. Furthermore, the test signals and parameters specifically described within this document for bench-top testing are not being encouraged or recommended for use on clinical scanners and to do so might result in scanner damage. No scanner operation beyond commercially released clinical performance is required from the MR Manufacturer.

The International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC) draw attention to the fact that it is claimed that compliance with this document may involve the use of a patent concerning gradient vibration given in <u>Clause 10</u>.

ISO and IEC take no position concerning the evidence, validity and scope of this patent right.

The holder of this patent right has assured ISO and IEC that he or she is willing to negotiate licences under reasonable and non-discriminatory terms and conditions with applicants throughout the world. In this respect, the statement of the holder of this patent right is registered with ISO and IEC (an example of the patent declaration is shown in Annex G). Further information may be obtained from:

Medtronic, Inc.
Open Innovation and Intellectual Property
8200 Coral Sea St. NE, MVN43
Mounds View, MN 55112
USA

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights other than those identified above. ISO and IEC shall not be held responsible for identifying any or all such patent rights.